China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · IEX Real-Time Price · USD
3.97
+1.90 (91.79%)
At close: Dec 29, 2023, 4:00 PM
2.72
-1.25 (-31.49%)
After-hours: Dec 29, 2023, 7:59 PM EST
China SXT Pharmaceuticals Revenue
China SXT Pharmaceuticals had revenue of $33.62K in the twelve months ending March 31, 2023. In the fiscal year ending March 31, 2023, China SXT Pharmaceuticals had annual revenue of $33.62K, a decrease of -90.09%.
Revenue (ttm)
$33.62K
Revenue Growth
-90.09%
P/S Ratio
1,233.50
Revenue / Employee
$431
Employees
78
Market Cap
41.47M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2023 | 33.62K | -305.51K | -90.09% |
| Mar 31, 2022 | 339.13K | -545.86K | -61.68% |
| Mar 31, 2021 | 884.99K | 554.56K | 167.83% |
| Mar 31, 2020 | 330.43K | 118.28K | 55.75% |
| Mar 31, 2019 | 212.16K | -1.10M | -83.89% |
| Mar 31, 2018 | 1.32M | 585.53K | 80.04% |
| Mar 31, 2017 | 731.51K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Spectral AI | 38.14M |
| Cara Therapeutics | 21.23M |
| LAVA Therapeutics | 9.63M |
| Aspira Women's Health | 9.18M |
| Evogene | 5.72M |
| Co-Diagnostics | 4.66M |
| BioSig Technologies | 141.00K |
SXTC News
- 2 months ago - China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule - GlobeNewsWire
- 3 months ago - China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split - GlobeNewsWire
- 1 year ago - China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split - GlobeNewsWire
- 1 year ago - China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million - GlobeNewsWire
- 2 years ago - Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC). - Accesswire
- 2 years ago - China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment - GlobeNewsWire
- 2 years ago - China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares - GlobeNewsWire
- 2 years ago - China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares - GlobeNewsWire